Takeda wanted to create something new in the cell therapy world by combining the technology with T cell engagers. A series of ...

The U.S. government remains shut down, with the FDA closed for new drug applications until further notice; cell and gene ...

When a new medicine enters the market, it’s common for the “high” initial list price to make headlines—which can lead to ...

The $48 million award, granted through the Advanced Research Projects Agency for Health, will help Kernal take its in vivo ...

As the industry loses one of its key female leaders in GSK CEO Emma Walmsley, BioSpace profiles the women leading the ...

Sanofi’s Orano Med-partnered radioligand therapy AlphaMedix achieved all primary efficacy endpoints, which included a measure of overall response rate, in the mid-stage ALPHAMEDIX-02 study.

In the Phase III FIBRONEER-IPF study, Jascayd demonstrated significant lung capacity improvements over placebo.

Six months after his controversial departure from the top spot at the FDA’s biologics division, Peter Marks has landed at Eli ...

Skye Bioscience's nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when ...

A new survey from CRB showed that most manufacturing initiatives in the U.S. made in response to tariffs are coming from Big ...

As industry leaders gather at the annual event in Phoenix, the cell and gene therapy space remains in a state of flux, with M ...

Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New ...